September 2017

Important New Products

• Kanuma (sebelipase alfa rce) is a recombinant human lysosomal acid lipase (rhLAL). ...(more)
• Lonsurf (trifluridine/ tipiracil (hydrochloride)) is comprised of an antineoplastic thymidine ...(more)
• Ocrevus (ocrelizumab) is a recombinant humanised anti-CD20 monoclonal antibody that ...(more)
• Pheburane (sodium phenylbutyrate) is an ammonia scavenger. Pheburane is indicated ...(more)
• Urorec (silodosin) is a selective antagonist of α_1A-adrenoreceptors primarily located ...(more)

New Indications

• Opdivo (nivolumab) is now indicated as monotherapy for the treatment of recurrent or ...(more)
• Ozurdex (dexamethasone) intravitreal implant is now indicated for the treatment of ...(more)

New Contraindications

• Daktarin Oral Gel (miconazole) is now contraindicated in combination with CYP2C9 ...(more)
• Eltroxin (levothyroxine sodium) is now contraindicated with acute myocarditis and ...(more)
• Neotigason (acitretin) is highly teratogenic and must not be used by patients who ...(more)
• Trileptal (oxcarbazepine) is now contraindicated with known hypersensitivity to ...(more)
• Victrelis (boceprevir) is now contraindicated in combination with lurasidone. ...(more)

Active Ingredient Naming Changes

In this release, MIMS Australia will be including the following INNs (International Non-proprietary Names) as well as Australian Approved Names (AANs) as part of our push to support the Therapeutic Goods Administration (TGA) active ingredient name changes project.  

MIMS will begin referring to these ingredients by their new names, however, users may continue to search by the old AANs if preferred. ...(more)